vs
艾伯维（ABBV）与通用电气医疗（OPCH）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是通用电气医疗的11.6倍（$16.6B vs $1.4B）。艾伯维净利率更高（10.9% vs 3.6%，领先7.3%）。通用电气医疗同比增速更快（12.2% vs 10.0%）。艾伯维自由现金流更多（$4.9B vs $130.2M）。过去两年艾伯维的营收复合增速更高（16.2% vs 13.0%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
通用电气医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，旗下设四大业务板块：医学影像（含分子成像、CT、磁共振、女性健康筛查及X线设备）、超声、患者护理解决方案（覆盖远程患者监测、麻醉呼吸护理、心脏病诊断、婴儿护理等）及制药相关业务。
ABBV vs OPCH — 直观对比
营收规模更大
ABBV
是对方的11.6倍
$1.4B
营收增速更快
OPCH
高出2.2%
10.0%
净利率更高
ABBV
高出7.3%
3.6%
自由现金流更多
ABBV
多$4.8B
$130.2M
两年增速更快
ABBV
近两年复合增速
13.0%
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $1.4B |
| 净利润 | $1.8B | $51.8M |
| 毛利率 | 72.6% | 19.0% |
| 营业利润率 | 27.3% | 5.9% |
| 净利率 | 10.9% | 3.6% |
| 营收同比 | 10.0% | 12.2% |
| 净利润同比 | 8354.5% | -3.8% |
| 每股收益（稀释后） | $1.02 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVOPCH
| Q4 25 | $16.6B | — | ||
| Q3 25 | $15.8B | $1.4B | ||
| Q2 25 | $15.4B | $1.4B | ||
| Q1 25 | $13.3B | $1.3B | ||
| Q4 24 | $15.1B | $1.3B | ||
| Q3 24 | $14.5B | $1.3B | ||
| Q2 24 | $14.5B | $1.2B | ||
| Q1 24 | $12.3B | $1.1B |
净利润ABBVOPCH
| Q4 25 | $1.8B | — | ||
| Q3 25 | $186.0M | $51.8M | ||
| Q2 25 | $938.0M | $50.5M | ||
| Q1 25 | $1.3B | $46.7M | ||
| Q4 24 | $-22.0M | $60.1M | ||
| Q3 24 | $1.6B | $53.9M | ||
| Q2 24 | $1.4B | $53.0M | ||
| Q1 24 | $1.4B | $44.8M |
毛利率ABBVOPCH
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | 19.0% | ||
| Q2 25 | 71.8% | 19.0% | ||
| Q1 25 | 70.0% | 19.7% | ||
| Q4 24 | 70.9% | 21.3% | ||
| Q3 24 | 70.9% | 20.1% | ||
| Q2 24 | 70.9% | 20.3% | ||
| Q1 24 | 66.7% | 20.8% |
营业利润率ABBVOPCH
| Q4 25 | 27.3% | — | ||
| Q3 25 | 12.1% | 5.9% | ||
| Q2 25 | 31.7% | 5.8% | ||
| Q1 25 | 28.0% | 5.9% | ||
| Q4 24 | -9.9% | 6.9% | ||
| Q3 24 | 26.5% | 6.7% | ||
| Q2 24 | 27.6% | 6.6% | ||
| Q1 24 | 22.7% | 6.0% |
净利率ABBVOPCH
| Q4 25 | 10.9% | — | ||
| Q3 25 | 1.2% | 3.6% | ||
| Q2 25 | 6.1% | 3.6% | ||
| Q1 25 | 9.6% | 3.5% | ||
| Q4 24 | -0.1% | 4.8% | ||
| Q3 24 | 10.8% | 4.2% | ||
| Q2 24 | 9.5% | 4.3% | ||
| Q1 24 | 11.1% | 3.9% |
每股收益（稀释后）ABBVOPCH
| Q4 25 | $1.02 | — | ||
| Q3 25 | $0.10 | $0.32 | ||
| Q2 25 | $0.52 | $0.31 | ||
| Q1 25 | $0.72 | $0.28 | ||
| Q4 24 | $-0.03 | $0.36 | ||
| Q3 24 | $0.88 | $0.31 | ||
| Q2 24 | $0.77 | $0.30 | ||
| Q1 24 | $0.77 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $309.8M |
| 总债务越低越好 | $58.9B | $1.2B |
| 股东权益账面价值 | $-3.3B | $1.4B |
| 总资产 | $134.0B | $3.5B |
| 负债/权益比越低杠杆越低 | — | 0.86× |
8季度趋势，按日历期对齐
现金及短期投资ABBVOPCH
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.7B | $309.8M | ||
| Q2 25 | $6.5B | $198.8M | ||
| Q1 25 | $5.2B | $171.4M | ||
| Q4 24 | $5.6B | $412.6M | ||
| Q3 24 | $7.3B | $483.0M | ||
| Q2 24 | $13.2B | $376.9M | ||
| Q1 24 | $18.1B | $219.5M |
总债务ABBVOPCH
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | $1.2B | ||
| Q2 25 | $63.0B | $1.1B | ||
| Q1 25 | $64.5B | $1.1B | ||
| Q4 24 | $60.3B | $1.1B | ||
| Q3 24 | $58.5B | $1.1B | ||
| Q2 24 | $58.0B | $1.1B | ||
| Q1 24 | $63.8B | $1.1B |
股东权益ABBVOPCH
| Q4 25 | $-3.3B | — | ||
| Q3 25 | $-2.6B | $1.4B | ||
| Q2 25 | $-183.0M | $1.4B | ||
| Q1 25 | $1.4B | $1.4B | ||
| Q4 24 | $3.3B | $1.4B | ||
| Q3 24 | $6.0B | $1.4B | ||
| Q2 24 | $6.8B | $1.4B | ||
| Q1 24 | $8.0B | $1.4B |
总资产ABBVOPCH
| Q4 25 | $134.0B | — | ||
| Q3 25 | $133.9B | $3.5B | ||
| Q2 25 | $137.2B | $3.4B | ||
| Q1 25 | $136.2B | $3.3B | ||
| Q4 24 | $135.2B | $3.4B | ||
| Q3 24 | $143.4B | $3.4B | ||
| Q2 24 | $141.9B | $3.3B | ||
| Q1 24 | $148.9B | $3.2B |
负债/权益比ABBVOPCH
| Q4 25 | — | — | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.82× | ||
| Q1 25 | 45.44× | 0.82× | ||
| Q4 24 | 18.15× | 0.79× | ||
| Q3 24 | 9.70× | 0.78× | ||
| Q2 24 | 8.56× | 0.79× | ||
| Q1 24 | 7.97× | 0.74× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $139.4M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $130.2M |
| 自由现金流率自由现金流/营收 | 29.4% | 9.1% |
| 资本支出强度资本支出/营收 | 2.0% | 0.6% |
| 现金转化率经营现金流/净利润 | 2.87× | 2.69× |
| 过去12个月自由现金流最近4个季度 | $17.8B | $220.7M |
8季度趋势，按日历期对齐
经营现金流ABBVOPCH
| Q4 25 | $5.2B | — | ||
| Q3 25 | $7.0B | $139.4M | ||
| Q2 25 | $5.2B | $90.3M | ||
| Q1 25 | $1.6B | $-7.2M | ||
| Q4 24 | $7.0B | $36.1M | ||
| Q3 24 | $5.4B | $160.4M | ||
| Q2 24 | $2.3B | $195.7M | ||
| Q1 24 | $4.0B | $-68.8M |
自由现金流ABBVOPCH
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | $130.2M | ||
| Q2 25 | $4.9B | $81.2M | ||
| Q1 25 | $1.4B | $-16.6M | ||
| Q4 24 | $6.8B | $25.8M | ||
| Q3 24 | $5.2B | $150.7M | ||
| Q2 24 | $2.0B | $185.9M | ||
| Q1 24 | $3.8B | $-74.6M |
自由现金流率ABBVOPCH
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | 9.1% | ||
| Q2 25 | 31.7% | 5.7% | ||
| Q1 25 | 10.5% | -1.2% | ||
| Q4 24 | 44.7% | 2.0% | ||
| Q3 24 | 35.9% | 11.8% | ||
| Q2 24 | 14.0% | 15.1% | ||
| Q1 24 | 31.3% | -6.5% |
资本支出强度ABBVOPCH
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.4% | 0.6% | ||
| Q2 25 | 1.7% | 0.6% | ||
| Q1 25 | 1.8% | 0.7% | ||
| Q4 24 | 1.9% | 0.8% | ||
| Q3 24 | 1.7% | 0.8% | ||
| Q2 24 | 1.7% | 0.8% | ||
| Q1 24 | 1.6% | 0.5% |
现金转化率ABBVOPCH
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | 2.69× | ||
| Q2 25 | 5.49× | 1.79× | ||
| Q1 25 | 1.27× | -0.15× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | 3.49× | 2.98× | ||
| Q2 24 | 1.66× | 3.69× | ||
| Q1 24 | 2.95× | -1.54× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
OPCH
| Commercial Customer | $1.3B | 87% |
| Government Customer | $172.8M | 12% |
| Patient Customer | $10.1M | 1% |
| Corporate Joint Venture | $1.9M | 0% |
